{
    "Trade/Device Name(s)": [
        "Proov Test"
    ],
    "Submitter Information": "MFB Fertility, Inc.",
    "510(k) Number": "K191462",
    "Predicate Device Reference 510(k) Number(s)": [
        "K040923"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "QKE"
    ],
    "Summary Letter Date": "January 22, 2020",
    "Summary Letter Received Date": "January 23, 2020",
    "Submission Date": "February 24, 2020",
    "Regulation Number(s)": [
        "21CFR862.1620"
    ],
    "Regulation Name(s)": [
        "Progesterone Test System"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Pregnanediol glucuronide (PdG)"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Competition principle"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "Strip test"
    ],
    "Document Summary": "FDA 510(k) summary for the Proov Test, a lateral flow immunoassay for qualitative detection of pregnanediol glucuronide in urine to confirm ovulation.",
    "Indications for Use Summary": "Intended for the detection of pregnanediol glucuronide (PdG, the major urine metabolite of progesterone) in urine as an aid for confirmation of ovulation.",
    "fda_folder": "Clinical Chemistry"
}